Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of tuvusertib in recurrent IDH-mutant ATRX-mutant astrocytoma
2025-521843-19-00Phase 2Authorised
- Sponsor
- Grupo Español de Investigación en Neurooncología
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tuvusertib in astrocytoma, sponsored by Grupo Español de Investigación en Neurooncología. Primary endpoint: 6-month progression-free survival rate. Planned start Dec 2025; status: authorised.
02
Drugs
tuvusertib
03
Conditions
astrocytoma
Beyond the preview
Go deeper on 2025-521843-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521843-19-00.